B细胞急性淋巴细胞白血病中对奥英妥珠单抗反应与耐药的基因组决定因素
该回顾性队列研究通过对接受奥英妥珠单抗(InO)治疗的B细胞急性淋巴细胞白血病患者样本进行全基因组、外显子组和/或转录组测序,探索反应与耐药的基因组决定因素。发现11%(3/27)的InO后复发样本获得CD22突变,而难治样本无CD22突变(0/16);CD22突变逃逸机制包括表位丢失和表位改变,部分伴超突变;TP53、ATM、CDKN2A功能丢失突变提示G1/S DNA损伤检查点受损;全基因组CRISPR/Cas9筛选发现DNTT缺失为耐药标志。
要点
- InO后复发样本中11%(3/27)获得CD22突变,难治样本0/16。
- CD22逃逸机制包括表位丢失(蛋白截短和失稳)和表位改变,部分病例伴超突变。
- TP53、ATM、CDKN2A功能丢失突变提示G1/S DNA损伤检查点受损参与逃逸InO诱导的凋亡。
核心结论
- 调节CD22表达和DNA损伤应答的遗传改变影响InO疗效。
- 研究强调明确CD22逃逸基础及在HSCT前根除残留病灶的重要性。
- 所鉴定的CD22靶向治疗逃逸机制超越抗原丢失,为改进治疗方法和克服耐药提供机会。
研究设计与样本
- 回顾性队列研究,纳入接受InO治疗的B细胞急性淋巴细胞白血病患者。
- 对InO治疗前和治疗后患者样本进行全基因组、外显子组和/或转录组测序。
- 对细胞系进行全基因组CRISPR/Cas9筛选。
- 试验注册号:NCT01134575、NCT01371630、NCT03441061。
主要发现
- InO后复发肿瘤样本中11%(3/27)观察到获得性CD22突变,难治样本中未观察到(0/16)。
- 每个样本存在多个CD22突变,CD22逃逸机制包括表位丢失(蛋白截短和失稳)和表位改变。
- 两例CD22突变病例为InO后超突变者,由易错DNA损伤修复(非同源/替代末端连接修复或错配修复缺陷)导致,提示超突变驱动逃逸CD22靶向治疗。
- CD22突变复发发生于InO及后续造血干细胞移植(HSCT)后,提示InO消除优势克隆,残留携带获得性CD22突变的亚克隆对InO耐药并 subsequently 扩增。
- 观察到TP53、ATM和CDKN2A获得性功能丢失突变,与G1/S DNA损伤检查点受损作为逃逸InO诱导凋亡的机制一致。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Inotuzumab ozogamicin (InO) is an antibody-drug conjugate that delivers calicheamicin to CD22-expressing cells. In a retrospective cohort of InO-treated patients with B-cell acute lymphoblastic leukemia, we sought to understand the genomic determinants of the response and resistance to InO. Pre- and post-InO-treated patient samples were analyzed by whole genome, exome, and/or transcriptome sequencing. Acquired CD22 mutations were observed in 11% (3/27) of post-InO-relapsed tumor samples, but not in refractory samples (0/16). There were multiple CD22 mutations per sample and the mechanisms of CD22 escape included epitope loss (protein truncation and destabilization) and epitope alteration. Two CD22 mutant cases were post-InO hyper-mutators resulting from error-prone DNA damage repair (nonhomologous/alternative end-joining repair, or mismatch repair deficiency), suggesting that hypermutation drove escape from CD22-directed therapy. CD22-mutant relapses occurred after InO and subsequent hematopoietic stem cell transplantation (HSCT), suggesting that InO eliminated the predominant clones, leaving subclones with acquired CD22 mutations that conferred resistance to InO and subsequently expanded. Acquired loss-of-function mutations in TP53, ATM, and CDKN2A were observed, consistent with a compromise of the G1/S DNA damage checkpoint as a mechanism for evading InO-induced apoptosis. Genome-wide CRISPR/Cas9 screening of cell lines identified DNTT (terminal deoxynucleotidyl transferase) loss as a marker of InO resistance. In conclusion, genetic alterations modulating CD22 expression and DNA damage response influence InO efficacy. Our findings highlight the importance of defining the basis of CD22 escape and eradication of residual disease before HSCT. The identified mechanisms of escape from CD22-targeted therapy extend beyond antigen loss and provide opportunities to improve therapeutic approaches and overcome resistance. These trials were registered at www.ClinicalTrials.gov as NCT01134575, NCT01371630, and NCT03441061.
引用
- Zhao Y, Short NJ, Kantarjian HM, et al. Genomic determinants of response and resistance to inotuzumab ozogamicin in B-cell ALL. Blood. 2024. PMID: 38551807. doi:10.1182/blood.2024023930
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。